Ultragenyx reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. For Q4 2025, Ultragenyx posted total revenues of USD 207 million, with product sales of USD 102 million and royalty revenue of USD 105 million. For FY 2025, total revenues reached USD 673 million, with product sales of USD 369 million and royalty revenue of USD 304 million. The company highlighted that the year ahead represents a significant turning point, with two potential product launches and a pivotal data readout anticipated to accelerate commercial revenue trajectory. Ultragenyx is also implementing a strategic restructuring plan aimed at reducing operating expenses and focusing resources on its highest-impact opportunities, as it advances the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9654092) on February 12, 2026, and is solely responsible for the information contained therein.